Deal Spotlight
August 14, 2026
Vivid Dx raises €13.2M Seed backed by Cedars-Sinai Intellectual Property Co, Jameel Investment Management Company, Oxford Sciences Enterprises
€13.2M
round size
seed
stage
The funding round closed on July 29, 2026, with participation from Cedars-Sinai Intellectual Property Co, Jameel Investment Management Company, and Oxford Sciences Enterprises. The company has no prior rounds and reported no total funds raised before this investment.
Vivid Dx develops a diagnostic platform for early cancer detection using liquid biopsy and circulating tumour DNA for non-invasive, accurate screening. The company is based in the United Kingdom and operates in Healthcare & Life Sciences.
Brouky tracks 269 deals in Healthcare & Life Sciences in the UK over the last 12 months with a median deal size of €11.2M.
Related insights
- Deal SpotlightAmber Electric raises EUR49M Series C+ backed by E.ON, ETF and others
- Deal SpotlightHyImpulse raises €50M Series A backed by ACE, Bayern Kapital, Join Capital, and North Ventures
- Deal SpotlightKanin Energy raises EUR94M Series C+ with Canada Growth Fund and S2G
- Deal SpotlightTandem Health raises EUR42.6M Series A with Amino Collective, Kinnevik, Northzone, Visionaries Club
Explore the full dataset
Brouky tracks 37,000+ investors and 122,000+ investments across 134,000+startups. Search by country, stage, and sector.